CeriBell (NASDAQ:CBLL) Receives $32.60 Average PT from Analysts

CeriBell (NASDAQ:CBLL) has received an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $32.60.

A number of research analysts have weighed in on CBLL shares. TD Cowen raised their price target on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Canaccord Genuity Group restated a “buy” rating and set a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th.

CeriBell Trading Down 7.2 %

Shares of CeriBell stock opened at $21.56 on Monday. The company has a 50 day moving average price of $22.80. CeriBell has a 52-week low of $18.69 and a 52-week high of $32.75.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts’ expectations of $17.55 million. Research analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

A number of large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers bought a new position in shares of CeriBell in the fourth quarter valued at about $320,000. FMR LLC acquired a new stake in CeriBell during the fourth quarter worth approximately $128,120,000. Corebridge Financial Inc. bought a new stake in shares of CeriBell during the fourth quarter worth approximately $158,000. Board of Trustees of The Leland Stanford Junior University acquired a new position in shares of CeriBell in the fourth quarter valued at approximately $16,143,000. Finally, Norges Bank bought a new position in shares of CeriBell during the fourth quarter worth approximately $422,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.